FDA Endorses Amgen Humira Biosimilar

Jul 13, 2016

Wall Street Journal

The second-largest selling drug worldwide could get some U.S. competition, according to an article in the Wall Street Journal. An FDA panel endorsed an alternative version of the current drug used to treat rheumatoid arthritis and other inflammatory diseases.

While not binding, the recommendation likely paves the way for FDA approval of the new drug. But it could take years to see those savings. Read the WSJ story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments